Treatment failure in endometrial carcinoma

Thomas W. Burke, Paul Heller, Joan E. Woodward, Susan A. Davidson, William J. Hoskins, Robert C. Park

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Endometrial carcinoma has been regarded as one of the more curable gynecologic malignancies. Clinical stage, grade, and depth of myometrial invasion are well-established prognostic variables. We examined the clinical course of 520 patients with endometrial carcinoma treated at Walter Reed Army Medical Center and the Naval Hospital, Bethesda, Maryland, between January 1, 1960 and December 31,1982. Life table 5-year survivals for stages la, Ib, II, III, and IV were 89, 92, 77, 27, and 0%, respectively. Compared with patients with grade 1 endometrial adenocarcinomas, significant decreases in survival were noted for patients with grade 2 or 3 endometrial, papillary endometrioid, serous papillary, and clear-cell tumors. There were six treatment-related deaths (1.2%). Thirty-eight patients (7.3%) developed recurrent disease, with a median time to recurrence of 15 months and a median survival of 21 months. Two of 11 patients with pelvic recurrence were salvaged by radiotherapy, whereas none of 27 patients with distant failure survived. Sixteen advanced-stage patients (3.1%) with persistent disease had a median survival of 4.5 months. Patients with advanced disease or unfavorable histologic subtypes responded poorly to conventional therapy. Current salvage treatments are largely ineffective. Combined-modality therapy and systemic adjuvant therapy should be prospectively evaluated in high-risk patient subgroups.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalObstetrics and Gynecology
Volume75
Issue number1
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Treatment Failure
Survival
Recurrence
Salvage Therapy
Combined Modality Therapy
Life Tables
Neoplasms
Adenocarcinoma
Radiotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Burke, T. W., Heller, P., Woodward, J. E., Davidson, S. A., Hoskins, W. J., & Park, R. C. (1990). Treatment failure in endometrial carcinoma. Obstetrics and Gynecology, 75(1), 96-101.
Burke, Thomas W. ; Heller, Paul ; Woodward, Joan E. ; Davidson, Susan A. ; Hoskins, William J. ; Park, Robert C. / Treatment failure in endometrial carcinoma. In: Obstetrics and Gynecology. 1990 ; Vol. 75, No. 1. pp. 96-101.
@article{796793ef9c3f4313b2fd73c38d883fd4,
title = "Treatment failure in endometrial carcinoma",
abstract = "Endometrial carcinoma has been regarded as one of the more curable gynecologic malignancies. Clinical stage, grade, and depth of myometrial invasion are well-established prognostic variables. We examined the clinical course of 520 patients with endometrial carcinoma treated at Walter Reed Army Medical Center and the Naval Hospital, Bethesda, Maryland, between January 1, 1960 and December 31,1982. Life table 5-year survivals for stages la, Ib, II, III, and IV were 89, 92, 77, 27, and 0{\%}, respectively. Compared with patients with grade 1 endometrial adenocarcinomas, significant decreases in survival were noted for patients with grade 2 or 3 endometrial, papillary endometrioid, serous papillary, and clear-cell tumors. There were six treatment-related deaths (1.2{\%}). Thirty-eight patients (7.3{\%}) developed recurrent disease, with a median time to recurrence of 15 months and a median survival of 21 months. Two of 11 patients with pelvic recurrence were salvaged by radiotherapy, whereas none of 27 patients with distant failure survived. Sixteen advanced-stage patients (3.1{\%}) with persistent disease had a median survival of 4.5 months. Patients with advanced disease or unfavorable histologic subtypes responded poorly to conventional therapy. Current salvage treatments are largely ineffective. Combined-modality therapy and systemic adjuvant therapy should be prospectively evaluated in high-risk patient subgroups.",
author = "Burke, {Thomas W.} and Paul Heller and Woodward, {Joan E.} and Davidson, {Susan A.} and Hoskins, {William J.} and Park, {Robert C.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "75",
pages = "96--101",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Burke, TW, Heller, P, Woodward, JE, Davidson, SA, Hoskins, WJ & Park, RC 1990, 'Treatment failure in endometrial carcinoma', Obstetrics and Gynecology, vol. 75, no. 1, pp. 96-101.

Treatment failure in endometrial carcinoma. / Burke, Thomas W.; Heller, Paul; Woodward, Joan E.; Davidson, Susan A.; Hoskins, William J.; Park, Robert C.

In: Obstetrics and Gynecology, Vol. 75, No. 1, 01.01.1990, p. 96-101.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment failure in endometrial carcinoma

AU - Burke, Thomas W.

AU - Heller, Paul

AU - Woodward, Joan E.

AU - Davidson, Susan A.

AU - Hoskins, William J.

AU - Park, Robert C.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Endometrial carcinoma has been regarded as one of the more curable gynecologic malignancies. Clinical stage, grade, and depth of myometrial invasion are well-established prognostic variables. We examined the clinical course of 520 patients with endometrial carcinoma treated at Walter Reed Army Medical Center and the Naval Hospital, Bethesda, Maryland, between January 1, 1960 and December 31,1982. Life table 5-year survivals for stages la, Ib, II, III, and IV were 89, 92, 77, 27, and 0%, respectively. Compared with patients with grade 1 endometrial adenocarcinomas, significant decreases in survival were noted for patients with grade 2 or 3 endometrial, papillary endometrioid, serous papillary, and clear-cell tumors. There were six treatment-related deaths (1.2%). Thirty-eight patients (7.3%) developed recurrent disease, with a median time to recurrence of 15 months and a median survival of 21 months. Two of 11 patients with pelvic recurrence were salvaged by radiotherapy, whereas none of 27 patients with distant failure survived. Sixteen advanced-stage patients (3.1%) with persistent disease had a median survival of 4.5 months. Patients with advanced disease or unfavorable histologic subtypes responded poorly to conventional therapy. Current salvage treatments are largely ineffective. Combined-modality therapy and systemic adjuvant therapy should be prospectively evaluated in high-risk patient subgroups.

AB - Endometrial carcinoma has been regarded as one of the more curable gynecologic malignancies. Clinical stage, grade, and depth of myometrial invasion are well-established prognostic variables. We examined the clinical course of 520 patients with endometrial carcinoma treated at Walter Reed Army Medical Center and the Naval Hospital, Bethesda, Maryland, between January 1, 1960 and December 31,1982. Life table 5-year survivals for stages la, Ib, II, III, and IV were 89, 92, 77, 27, and 0%, respectively. Compared with patients with grade 1 endometrial adenocarcinomas, significant decreases in survival were noted for patients with grade 2 or 3 endometrial, papillary endometrioid, serous papillary, and clear-cell tumors. There were six treatment-related deaths (1.2%). Thirty-eight patients (7.3%) developed recurrent disease, with a median time to recurrence of 15 months and a median survival of 21 months. Two of 11 patients with pelvic recurrence were salvaged by radiotherapy, whereas none of 27 patients with distant failure survived. Sixteen advanced-stage patients (3.1%) with persistent disease had a median survival of 4.5 months. Patients with advanced disease or unfavorable histologic subtypes responded poorly to conventional therapy. Current salvage treatments are largely ineffective. Combined-modality therapy and systemic adjuvant therapy should be prospectively evaluated in high-risk patient subgroups.

UR - http://www.scopus.com/inward/record.url?scp=0025058639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025058639&partnerID=8YFLogxK

M3 - Article

C2 - 2296431

AN - SCOPUS:0025058639

VL - 75

SP - 96

EP - 101

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 1

ER -

Burke TW, Heller P, Woodward JE, Davidson SA, Hoskins WJ, Park RC. Treatment failure in endometrial carcinoma. Obstetrics and Gynecology. 1990 Jan 1;75(1):96-101.